TY - JOUR
T1 - Contemporary Treatment of Pulmonary Arterial Hypertension A U.S. Perspective
AU - Sahay, Sandeep
AU - Chakinala, Murali M.
AU - Kim, Nick H.
AU - Preston, Ioana R.
AU - Thenappan, Thenappan
AU - McLaughlin, Vallerie V.
N1 - Publisher Copyright:
Copyright © 2024 by the American Thoracic Society.
PY - 2024/9/1
Y1 - 2024/9/1
N2 - Pulmonary arterial hypertension (PAH) is a complex fatal condition that requires aggressive treatment with close monitoring. Significant progress has been made over the last three decades in the treatment of PAH, but, despite this progress survival has remained unacceptably low. In the quest to improve survival, therapeutic interventions play a central role. In the last few years, there have been remarkable attempts to identify novel treatments. Finally, we have had a breakthrough with the discovery of the fourth treatment pathway in PAH. Activin signaling inhibition distinguishes itself as a potential antiproliferative intervention as opposed to the traditional therapies, which mediate their effect primarily by vasodilatation. With this novel treatment pathway, we stand at an important milestone with an exciting future ahead and the natural question of when to use an activin signaling inhibitor for the treatment of PAH. In this state-of-the-art review, we focus on the placement of this novel agent in the PAH treatment paradigm, based on the available evidence, with special focus on the U.S. patient population. This review also provides an expert opinion of the current treatment algorithm in important subgroups of patients with comorbidities from the U.S. perspective.
AB - Pulmonary arterial hypertension (PAH) is a complex fatal condition that requires aggressive treatment with close monitoring. Significant progress has been made over the last three decades in the treatment of PAH, but, despite this progress survival has remained unacceptably low. In the quest to improve survival, therapeutic interventions play a central role. In the last few years, there have been remarkable attempts to identify novel treatments. Finally, we have had a breakthrough with the discovery of the fourth treatment pathway in PAH. Activin signaling inhibition distinguishes itself as a potential antiproliferative intervention as opposed to the traditional therapies, which mediate their effect primarily by vasodilatation. With this novel treatment pathway, we stand at an important milestone with an exciting future ahead and the natural question of when to use an activin signaling inhibitor for the treatment of PAH. In this state-of-the-art review, we focus on the placement of this novel agent in the PAH treatment paradigm, based on the available evidence, with special focus on the U.S. patient population. This review also provides an expert opinion of the current treatment algorithm in important subgroups of patients with comorbidities from the U.S. perspective.
KW - activin signaling inhibitor
KW - PAH
KW - risk stratification
KW - sotatercept
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85202039943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85202039943&partnerID=8YFLogxK
U2 - 10.1164/rccm.202405-0914SO
DO - 10.1164/rccm.202405-0914SO
M3 - Article
C2 - 38984912
AN - SCOPUS:85202039943
SN - 1073-449X
VL - 210
SP - 581
EP - 592
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 5
ER -